Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. - Wikidata - awgldk - TriplyDB

Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.

Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.

http://www.wikidata.org/entity/Q46984034

about

Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain.Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis.Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues.Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.Involvement Of Vascular Aldosterone Synthase In Phosphate-Induced Osteogenic Transformation Of Vascular Smooth Muscle Cells.Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II - Management of Various Cardiovascular Complications.Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A.Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney disease The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial Incidence of sudden cardiac death in adults with end-stage renal disease: a systematic review and meta-analysis Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review Is low dialysate potassium ever indicated in outpatient hemodialysis?Management of hyperkalaemia in chronic kidney disease.The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients.Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists.Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis.Pharmacotherapy of Hypertension in Chronic Dialysis Patients.Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis.Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations.Sudden Cardiac Death Among Hemodialysis Patients.RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan.The prognostic value of oxidative stress and inflammation in Chinese hemodialysis patients.Aldosterone, mortality, cardiovascular events and reverse epidemiology in end stage renal disease.Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.Spironolactone is effective in treating hypokalemia among peritoneal dialysis patients.The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature.Aldosterone and Insulin Resistance: Vicious Combination in Patients on Maintenance Hemodialysis.Complete remission of hypertension in a hemodialysis patient after adrenalectomy for primary aldosteronism and renal transplantation.Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.Therapeutic Interference With Vascular Calcification-Lessons From Klotho-Hypomorphic Mice and Beyond.SGK1 induces vascular smooth muscle cell calcification through NF-κB signaling.

P2860

Q30235413-473CDBB5-33F9-48FF-86D2-66A1F57123E6 Q30248239-B7A314EF-FDCB-4045-9CB5-601369001B37 Q31004378-331A3D56-9260-4695-B566-13DD141B18A3 Q31143932-267D498F-113F-4D59-B821-F88F0A365590 Q33700483-BA46AFA2-2558-440E-B015-87166A58EC96 Q33871492-C98ED8CD-16B5-429D-873A-2DFFA85E8301 Q35904403-90471828-B19B-4B1E-830F-2F7F9357070E Q35992464-6D1E6162-2BC6-452D-BD54-E6A49A573689 Q36021782-3DD432FC-5AEB-4708-83AB-F7226088335B Q36025666-1253B9B5-4790-4B15-8070-76DD20E08C2B Q36073131-04576570-2269-4999-AA70-2DBCA6571BB5 Q36265484-3D685EF1-2574-40AD-B44C-D213D7B57D93 Q38196437-3C943F4E-D643-4050-A0BF-A0467BABB987 Q38249892-C0A25683-9CC1-485D-893D-83ED280CE251 Q38374536-CBE5ACC2-9150-4170-AA15-EED3999612F1 Q38409063-5BC49C02-5762-4F7A-B785-18B06DCBCFE3 Q38525979-147DFF36-9493-40EE-B186-D89B0A77C7ED Q38560705-A062722C-4A2E-481D-8992-ACC9441966A9 Q38740191-4CCD0A95-4BE1-4567-BBFB-F638FFE8490B Q38746216-DE3D6EC2-FE7F-426B-9FB7-7BBA6B4C80C6 Q38802032-AB96EB7E-6A78-46A8-9B18-424370A7F1C6 Q38815486-045F6297-E87E-4DE6-9187-AAD29F69B95A Q38817871-A7622056-E498-4692-AD65-E6EB9EEA5CEC Q38818606-55500BE8-C380-4F54-B34A-38708DCF3113 Q38837657-C310564E-03BE-43BF-AB47-B022FC7FDD20 Q39096879-306B69EE-4F37-47B7-B697-16F58EB655EB Q39145628-A75BB83A-21E8-4E1D-AF19-A9DABBFA93E9 Q40073611-0F8B57C0-97A6-4A79-A417-760B329778B8 Q40526621-3187BDF2-E8C7-4C33-9919-78D8F8E828F4 Q40569514-3637C670-4257-4FD4-BDFD-95DC14C9B5F9 Q40679965-8001E575-C35C-46A7-ADF3-2B9B4B5423D8 Q41877664-B16D8F07-1A82-4E6C-B530-DDB931EB075B Q47134104-D7A30C7D-512A-44A6-99C6-B1075D5BA866 Q48025446-FE1D6F6F-DF29-4577-9F3B-8C5CC295978C Q48357684-CFF4F3EB-A2C9-4909-ADE0-7B71E8629DFC Q49484949-76909C29-45D9-48BB-BBE8-208476F749AD Q52688314-1CEF95F2-DEAB-4C1E-9034-93A90073FB1B Q52690991-D666A5C9-35ED-4A27-BC22-CC528225BDB1 Q54960616-11F04AA6-CEFD-4048-A7C0-483FF2ED6BE0 Q54976557-E40B54D1-5102-4797-9710-14840928BBF4

P2860

Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.

http://www.wikidata.org/entity/Q46984034

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Spironolactone reduces cardiov ...... lity in hemodialysis patients.

@en

Spironolactone reduces cardiov ...... lity in hemodialysis patients.

@nl

type

label

Spironolactone reduces cardiov ...... lity in hemodialysis patients.

@en

Spironolactone reduces cardiov ...... lity in hemodialysis patients.

@nl

prefLabel

Spironolactone reduces cardiov ...... lity in hemodialysis patients.

@en

Spironolactone reduces cardiov ...... lity in hemodialysis patients.

@nl

P1433

Q46984034-A01BF8BB-63E1-49E7-9A68-7C54950B70AE

P1476

Q46984034-E5ED6F95-5FEE-44FB-AC86-EEC11885D380

P2093

Q46984034-2929E8F5-391E-4676-9E0D-B6B63359EAE0

Q46984034-48E0E128-6929-462F-8BE9-35510CEBD694

Q46984034-60B6EB73-EE45-4686-8FD3-3010699F12A4

Q46984034-619B5CDB-B4A6-44E9-AE9B-3711075650E0

Q46984034-6E2B20E5-A798-4732-9D8A-088AEDD79A66

Q46984034-725A8026-BEBE-47CD-83D6-6EE44A523F4B

Q46984034-8116CAC0-DB55-4C4F-8B4C-B8E84F81713A

Q46984034-A77CBD3B-B6CA-4CB0-9504-801C04DF0169

Q46984034-A796374C-7A21-4F45-803E-B713EF4807F1

Q46984034-B2EF5987-A640-4725-832A-5D1D0876F179

P304

Q46984034-855AB933-4BBA-474C-832A-C70535F9117B

P31

Q46984034-F64A8E66-4F43-456A-A026-A90F970228A1

P356

Q46984034-D3582F6D-2FF9-48CC-97E7-554BB38F43CC

P407

Q46984034-38A92679-7E08-4602-BDBA-A9517E0EFB4A

P433

Q46984034-01F1EEAA-C532-4E42-8DA8-9AD0E5FE05D6

P478

Q46984034-A7B24DB2-8383-4E56-ADE9-C698972CD9C5

P577

Q46984034-3909B909-C220-421B-A216-9B1B6AFFF78D

P5875

Q46984034-1636CD61-88DA-4F39-AD4A-CBC0724277C8

P698

Q46984034-53FA48B5-ED36-43AB-956E-2A245DF9F02B

P921

Q46984034-77F0EE40-A6A8-4B66-9C92-2996E28D8E68

Q46984034-81606E5E-4FC9-4158-A057-78F556A0E996

P356

J.JACC.2013.09.056

P1433

Journal of the American College of Cardiology

P1476

Spironolactone reduces cardiov ...... lity in hemodialysis patients.

@en

P2093

Hatsumi Sugiyama

http://www.w3.org/2001/XMLSchema#string

Hiromichi Ohmura

http://www.w3.org/2001/XMLSchema#string

Kazuo Arihara

http://www.w3.org/2001/XMLSchema#string

Nobuo Shio

http://www.w3.org/2001/XMLSchema#string

Shinji Kageyama

http://www.w3.org/2001/XMLSchema#string

Toru Yakushigawa

http://www.w3.org/2001/XMLSchema#string

Toshikazu Sugiyama

http://www.w3.org/2001/XMLSchema#string

Yasuo Mori

http://www.w3.org/2001/XMLSchema#string

Yasushi Shimada

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Matsumoto

http://www.w3.org/2001/XMLSchema#string

P304

528-536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2013.09.056

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258252086

http://www.w3.org/2001/XMLSchema#string

P698

24184249

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio